文档介绍：18FFDG显像在乳腺癌新辅助化疗疗效评价中的应用
(作者:___________单位: ___________邮编: ___________)

【摘要】目的探讨18FFDG PET显像评价乳腺癌新辅助化疗疗效应用价值。方法对31例经细针穿刺或针吸细胞活检确诊为原发性乳腺癌的患者在FAC方案化疗前、后分别行18FFDG PET显像,根据PET显像结果计算乳腺癌病灶放射性摄取比值(T/NT);3个疗程结束后评价疗效,以WHO制定的肿瘤化疗评价标准分为有效组[R(+),n=22]和无效组[R(-),n=9];以第3疗程结束后T/NT比值降低百分率≥10%、≥20%、≥30%作为监测治疗有无反应的阈值进行疗效判定。临床军医杂志(Clin J Med Offic)2007年12月第35卷第6期结果化疗前R(+)组和R(-)组T/±、±(),化疗第3疗程后R(+)组T/±±(),而R(-)组T/±±();R(+)组T/NT比值降低的百分率为(±6)%,明显高于R(-)组(±6)%();若以第3疗程结束后T/N比值降低百分率≥10%、≥
20%、≥30%作为监测治疗有无反应的阈值,18FFDG PET评价疗效的灵敏度、特异性分别为100%、89%、82%和85%、92%、100%。结论 18FFDG PET显像对乳腺癌新辅助化疗早期疗效的评价具有一定的临床价值。
【关键词】 18FFDG;乳腺肿瘤;新辅助化疗;疗效
Abstract: Objective To study the application value of response to neoadjuvant chemotherapy in breast cancer using 18Ffluorodeoxyglucose (FDG) positron emission tomography (PET). Methods Thirtyone primary breast cancer patients finally diagnosed by fine needle aspiration examination accepted 18FFDG PET imaging examination before and after three cycles of FAC chemotherapy. Calculation was carried out for the tumortonormal tissue background (T/NT) value in the focus of the cancer. According to WHO criterion, the patients were divided into two groups after therapy, . effective group [R(+), n=22] and noneffective group [R(-), n=9]. According to the T/NT declini